Mapping genetic interactions to improve cancer treatment
Official title: Expanding the cancer paralog genetic interaction map to enable precision oncology
Funded at Fred Hutchinson Cancer Center · NIH-11039934 · Data updated 2026-11-12
This study is looking for new ways to improve cancer treatment for people with non-small cell lung cancer by finding specific genes that could help overcome the challenges of drug resistance, aiming to create more personalized and effective treatment options for patients who need them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $548,562 |
| NIH project number | 5R01CA262556-02 |
| Project ID | NIH-11039934 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those who have developed resistance to existing treatments.
✕Less likely to help
Patients with cancer types other than non-small cell lung cancer may not benefit from this research.
What this research studies
This research aims to enhance cancer treatment by identifying new genetic targets that can help overcome drug resistance in non-small cell lung cancer. Using advanced techniques like genome-wide CRISPR knockout screens, the team will explore the functions of gene families, particularly those with redundant roles, to uncover potential new therapies. By focusing on paralogous genes, which make up a significant portion of the human genome, the research seeks to develop innovative approaches to personalize cancer treatment for patients. This could lead to more effective options for those who currently have limited therapeutic choices.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer therapies, improving survival rates for patients with non-small cell lung cancer.
How similar studies have gone: Other research has shown promise in using CRISPR technology to identify new cancer targets, indicating that this approach has potential for success.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Berger, Alice — Fred Hutchinson Cancer Center
- Study coordinator: Berger, Alice
Related research
Other NIH-funded projects on the same topics.
-
How brain glia prune neuron fragments in a worm model
Researchers study how brain support cells called glia remove pieces of living neurons in a tiny worm to learn about brain aging and diseases like Alzheimer's.
-
Understanding and Targeting Lineage Plasticity in Prostate Cancer with Genomic-Based Neoadjuvant Therapy
A broad research program at Fred Hutchinson Cancer Center is exploring how aggressive prostate cancers change their cell states in response to therapy and how to block these changes.
-
Personalized cancer drug testing on patient tumor cells
Aiming to test many FDA-approved cancer drugs on a patient’s own tumor cells to identify effective options when standard therapies fail.
-
MOSAAIC: Using health records to track heart disease in Asian American Communities
A big, dedicated effort is testing whether electronic health records can more quickly and accurately track heart and blood vessel problems in Asian American populations.
-
Targeting gut microbes to prevent progression to multiple myeloma
Researchers are testing how specific gut bacteria might trigger immune changes linked to early blood cancer stages and whether targeting these microbes could help prevent progression to multiple myeloma.
-
eDyNAmiC: Understanding extrachromosomal DNA in cancer and how it drives aggressiveness
A cancer research project at Fred Hutchinson Cancer Center is studying abnormal circular DNA pieces (ecDNA) that help cancers grow and resist treatment, with the aim of finding ways to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.